EnzymeBioSystems announced that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma. Xenografting is an established and reliable preclinical method for testing anti-tumor therapies. Xenografting is a scientific technique involving transplantation of tissue from one species to a different species.

In particular, xenografting of human tumor tissue into immuno compromised mice provides a better model of tumor cells than in vitro studies. Methyl amooranin is a structurally modified version of a plant-based natural product. Management is in the process of preparing the required methyl amooranin studies to apply for an Investigational New Drug Application with the FDA.

The company plans to seek the use of methyl amooranin in the prevention of breast cancer.